[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559143":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":58,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":24,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":24,"overallStatus":35,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Micronized purified flavonoid fraction (Daflon ®)","ACTIVE_COMPARATOR","Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice\u002Fdaily for 3 months.",[13],"Drug: Micronized purified flavonoid fraction (Daflon ®)",{"label":15,"type":16,"description":17,"interventionNames":18},"Glue embolization","EXPERIMENTAL","Patients will receive transcatheter glue embolization.",[19],"Other: Glue embolization",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":6,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Mohamed I Eleissawy, MD","CONTACT","00201110036328","mohamed.elesawy@med.tanta.edu.eg",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Tanta","ElGharbia","31527","Egypt","EG",{"type":42,"coordinates":43},"Point",[44,45],31.00192,30.78847,{"lat":45,"lon":44},[48,49,52,54,56],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},{"name":50,"role":51,"phone":24,"phoneExt":24,"email":24},"Hossam M Khalil, MD","PRINCIPAL_INVESTIGATOR",{"name":53,"role":51,"phone":24,"phoneExt":24,"email":24},"Mai N Ageez, MD",{"name":55,"role":51,"phone":24,"phoneExt":24,"email":24},"Mohamed E Eleiwa, MD",{"name":57,"role":51,"phone":24,"phoneExt":24,"email":24},"Abdelrahman A Nagy, MD",{"type":51,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Mohamed Ibrahim Adel Eleissawy","Lecturer of Vascular and Endovascular Surgery, Faculty of Medicine, Tanta University, Tanta, Egypt.","100559143","glue-embolization-vs-conservative-treatment-for-pelvic-congestion-syndrome-100559143",false,"NCT06560294","Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome","Glue Embolization Versus Conservative Treatment for Pelvic Congestion Syndrome: A Randomized Trial","Inclusion Criteria:\n\n* Women aged from 30 to 50 years.\n* Complaining from pelvic congestion syndrome.\n\nExclusion Criteria:\n\n* Pregnant women at any gestational age, women who gave birth less than 12 months ago, and breastfeeding mothers.\n* Patients who are treated with opiates to reduce pelvic pain in the period before the study.\n* Patient with history of contrast allergy\n* Patient with renal impairment\n* Patient has alternative gynecological cause of chronic pelvic pain as pelvic inflammatory disease (PID), endometriosis, fibroid, adenomyosis, ovarian cyst\n* Patient underwent any previous intervention for pelvic congestion syndrome as laparoscopy or surgery.","FEMALE","30 Years","50 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"NA","The aim of this study is to compare glue embolization and conservative treatment for pelvic congestion syndrome regarding safety and efficacy.",[79,80],"Glue Embolization","Pelvic Congestion Syndrome","2025-08-18",{"date":83,"type":84},"2025-08-19","ACTUAL",{"date":86,"type":84},"2024-08-17",{"date":88,"type":73},"2025-10-01",{"name":5,"class":6},1]